January 9, 2026 — Leads & Copy — Johnson & Johnson (NYSE: JNJ) has reached a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients.
The agreement aligns with President Trump’s requests and exempts the company’s pharmaceutical products from tariffs.
Johnson & Johnson is participating in TrumpRx.gov, a direct-to-patient platform, which will allow millions of Americans to purchase medicines from Johnson & Johnson at significantly discounted rates. The Company is also enabling American patients to access medicines at comparable prices to other developed countries and is providing Medicaid program access at comparable prices to other developed countries.
Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, stated that the agreement demonstrates the positive outcomes when the public and private sectors collaborate. He also said that Johnson & Johnson is answering President Trump’s call to lower drug prices while maintaining its role in improving and saving lives and ensuring that the United States continues to lead in healthcare innovation.
Johnson & Johnson is delivering on its previously announced $55 billion investment to support U.S. manufacturing, research and development, and technology investments by early 2029. In the last 10 months, the company has initiated billions of dollars in investment in U.S. manufacturing. The company’s goal is to manufacture the majority of its advanced medicines in the U.S. to meet the needs of U.S. patients.
As part of the $55 billion investment, Johnson & Johnson is announcing two new U.S. manufacturing facilities, including a next-generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug product manufacturing facility in North Carolina.
Construction is in progress on its $2 billion biologics manufacturing facility in Wilson, North Carolina, which will create approximately 5,000 skilled manufacturing and construction jobs. Johnson & Johnson is hiring advanced manufacturing employees to work at the facility.
In September, the Company secured a new 160,000+ square foot dedicated biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion commitment over the next 10 years will create approximately 120 new jobs in North Carolina.
Johnson & Johnson expects to announce additional U.S. investments later this year.
Learn more at www.jnj.com.
Source: Johnson & Johnson
